Home > Publications Database > Inconsistent primary motor cortex glucose hypometabolism in primary lateral sclerosis. > print

001     278793
005     20260105130926.0
024 7 _ |a pmc:PMC12092561
|2 pmc
024 7 _ |a 10.1007/s00415-025-13089-x
|2 doi
024 7 _ |a pmid:40392424
|2 pmid
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2025-00629
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lehto, Annaliis
|0 P:(DE-2719)9002327
|b 0
|e First author
245 _ _ |a Inconsistent primary motor cortex glucose hypometabolism in primary lateral sclerosis.
260 _ _ |a [Darmstadt]
|c 2025
|b Steinkopff
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1748946576_5050
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Primary lateral sclerosis (PLS) is a rare neurodegenerative disorder and a model for upper motor neuron degeneration, which is believed to begin in the primary motor cortex. However, clinical observation suggests that not all PLS cases show primary motor cortex glucose hypometabolism on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET). We aimed to assess the reliability of FDG-PET in identifying motor cortex hypometabolism over disease course in a sample of patients with PLS.Baseline FDG-PET data from nine consecutive PLS patients were analyzed. At least one follow up assessment was available for five patients. We extracted the average FDG-PET signal in the primary motor cortex and other motor regions and calculated the covariate-corrected z scores based on data of healthy controls from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.Among the nine patients evaluated, only four demonstrated glucose hypometabolism in the primary motor cortex across available baseline and follow up assessments. Glucose metabolism of motor regions declined over time in some patients, whereas others maintained stable levels despite a worsening in symptom severity.Primary motor cortex hypometabolism in PLS patients is less consistent than previously reported, and the absence of this hypometabolic sign should not be considered as irrefutable evidence against PLS in the diagnostic process. The findings of our study underline the heterogeneity of PLS, indicating that more precise diagnostic tools would be beneficial to confirm a PLS diagnosis at an earlier stage.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebral glucose metabolism
|2 Other
650 _ 7 |a FDG-PET
|2 Other
650 _ 7 |a Primary lateral sclerosis
|2 Other
650 _ 7 |a Primary motor cortex
|2 Other
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Motor Cortex: metabolism
|2 MeSH
650 _ 2 |a Motor Cortex: diagnostic imaging
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18
|2 MeSH
650 _ 2 |a Glucose: metabolism
|2 MeSH
650 _ 2 |a Motor Neuron Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Motor Neuron Disease: metabolism
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
700 1 _ |a Schumacher, Julia
|0 P:(DE-2719)9002248
|b 1
700 1 _ |a Kurth, Jens
|0 0000-0001-6864-4513
|b 2
700 1 _ |a Krause, Bernd J
|b 3
700 1 _ |a Kasper, Elisabeth
|0 P:(DE-2719)9000419
|b 4
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 5
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 6
|e Last author
700 1 _ |a Initiative, Alzheimer’s Disease Neuroimaging
|b 7
|e Collaboration Author
773 _ _ |a 10.1007/s00415-025-13089-x
|g Vol. 272, no. 6, p. 410
|0 PERI:(DE-600)1421299-7
|n 6
|p 410
|t Journal of neurology
|v 272
|y 2025
|x 0367-004X
856 4 _ |u https://pub.dzne.de/record/278793/files/DZNE-2025-00629%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278793/files/DZNE-2025-00629.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/278793/files/DZNE-2025-00629%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278793/files/DZNE-2025-00629.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278793
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002248
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000419
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2380559
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)5000014
|k AG Storch
|l Non-Motor Symptoms in Parkinson's disease
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)5000014
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21